syntenin-1 Inhibitors
Syntenin-1 inhibitors form a versatile class of chemicals designed to target distinct cellular pathways, indirectly influencing the expression and function of syntenin-1. These compounds act on key signaling cascades, disrupting the intricate regulatory networks governing syntenin-1-mediated cellular processes. One example within this class is Brefeldin A, which interferes with vesicular transport, thereby indirectly impacting syntenin-1 by disrupting its intracellular trafficking. This disruption can lead to alterations in syntenin-1 localization and function within the cell. Wortmannin and LY294002, both PI3K inhibitors, influence syntenin-1 by perturbing the PI3K/AKT pathway, which is essential for syntenin-1-mediated events. By inhibiting PI3K, these compounds indirectly modulate syntenin-1 function, highlighting the interconnectedness of cellular pathways involved in syntenin-1 regulation.
The MAPK pathway serves as a focal point for several syntenin-1 inhibitors, including SB 203580, U0126, and SP600125, targeting p38 MAPK, MEK1/2, and JNK, respectively. Chemicals like Rapamycin and Trametinib target mTOR and MEK1/2, respectively, influencing syntenin-1 through these interconnected pathways. By modulating these signaling cascades, these inhibitors offer a nuanced approach to indirectly impacting syntenin-1 function. DNA-damaging agents, including 5-Fluorouracil and Cisplatin, indirectly inhibit syntenin-1 by disrupting DNA repair mechanisms in which syntenin-1 participates. Epigenetic regulation is addressed by VX-11e, an HDAC inhibitor that alters histone acetylation, impacting syntenin-1 expression. This compound introduces an epigenetic layer to syntenin-1 regulation, expanding the repertoire of potential modulatory strategies. A769662, an AMPK activator, indirectly inhibits syntenin-1 by modulating cellular energy status, intersecting with syntenin-1's involvement in energy-related signaling pathways. This highlights the role of cellular energetics in syntenin-1 regulation and introduces metabolic modulation as a potential avenue for influencing syntenin-1 function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts vesicular transport from the endoplasmic reticulum (ER) to the Golgi apparatus by inhibiting ADP-ribosylation factors (ARFs). This disturbance indirectly affects syntenin-1, as its intracellular trafficking and interactions are reliant on intact vesicular transport. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor, hampers the PI3K/AKT pathway. This disruption reverberates to downstream processes, impacting syntenin-1 expression and function. The PI3K/AKT pathway is implicated in syntenin-1-mediated cellular events, making Wortmannin an indirect inhibitor. | ||||||
PD 169316 | 152121-53-4 | sc-204168 sc-204168A sc-204168B sc-204168C | 1 mg 5 mg 10 mg 25 mg | $88.00 $156.00 $281.00 $461.00 | 3 | |
SB 203580 is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK). As syntenin-1 is modulated by the MAPK pathway, particularly p38 MAPK, this inhibitor indirectly affects syntenin-1 by disrupting the signaling cascade that influences its expression and cellular activities. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, another PI3K inhibitor, affects syntenin-1 by impeding the PI3K pathway. Since syntenin-1 interacts with proteins involved in this pathway, LY294002 indirectly inhibits syntenin-1 by disrupting its regulatory network and downstream signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, disrupts the mTOR signaling pathway. Since mTOR interacts with syntenin-1 and regulates its stability, Rapamycin indirectly inhibits syntenin-1 by interfering with mTOR-mediated processes that affect syntenin-1 expression and cellular functions. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
5-FU, a thymidylate synthase inhibitor, affects DNA synthesis. Given syntenin-1's involvement in DNA damage repair processes, 5-FU indirectly inhibits syntenin-1 by disrupting cellular functions associated with DNA repair, consequently impacting syntenin-1-mediated activities. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin, a DNA cross-linking agent, induces DNA damage. Since syntenin-1 is implicated in DNA repair mechanisms, Cisplatin indirectly inhibits syntenin-1 by promoting DNA damage and disrupting the cellular processes where syntenin-1 plays a role. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib inhibits MEK1 and MEK2, crucial components of the MAPK/ERK pathway. By disrupting this pathway, Trametinib indirectly affects syntenin-1, as syntenin-1 expression and function are modulated by MAPK signaling cascades. | ||||||
VX-11e | 896720-20-0 | sc-507301 | 10 mg | $180.00 | ||
VX-11e, an HDAC inhibitor, influences histone acetylation. Since syntenin-1 expression is regulated epigenetically, VX-11e indirectly inhibits syntenin-1 by altering the acetylation status of histones, thereby modulating the transcriptional control of syntenin-1 gene expression. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
A769662, an AMP-activated protein kinase (AMPK) activator, indirectly inhibits syntenin-1 by modulating cellular energy status. As syntenin-1 is involved in energy-related signaling pathways, A769662 indirectly influences syntenin-1 expression and functions through AMPK activation. | ||||||